CVS Health (NYSE: CVS) Stock Rises on Strong Q1 Earnings and RBC Capital Upgrade

Font: Financial Modeling Prep  • May 07, 2026

• RBC Capital reiterated an "Outperform" rating for CVS Health, raising its stock price target to $107.00 from $90.00.
• CVS Health reported robust Q1 financial results, with total revenues of $100.43 billion, exceeding analyst expectations, and adjusted earnings per share (EPS) increasing 14.2% to $2.57.
• The company raised its full-year 2026 earnings guidance to a range of $7.30 to $7.50 per share, reflecting strong segment performance and improved cost controls.

CVS Health Corporation (NYSE:CVS) is a diversified health services company, operating a large chain of retail pharmacies across the United States. The company also owns Aetna, a major health insurance provider, making it a key player in both the pharmacy and healthcare benefits industries. This strategic positioning underpins its strong market presence.

On May 7, 2026, investment firm RBC Capital reiterated its "Outperform" rating for CVS Health. An "Outperform" rating signifies that the analyst expects the CVS stock to perform better than the overall market. The firm also raised its stock price target, or expected stock price, to $107.00 from its previous target of $90.00, signaling increased confidence in the company's future performance.

This positive analyst view is strongly supported by the company's recent financial results. For its first quarter, CVS Health reported total revenues of $100.43 billion, a 6.2% increase from the same period last year. As highlighted by Zacks, this impressive figure surpassed analyst expectations of $94.37 billion, demonstrating robust revenue growth in the healthcare sector.

The company’s profitability also showed significant strength. It posted an adjusted earnings per share (EPS) of $2.57, which is a 14.2% increase from the year-ago quarter. This substantial EPS growth was driven by strong performance in its Health Services and Health Care Benefits segments, which saw revenues rise by 11% and 3.3% respectively, underscoring the effectiveness of its diversified business model.

Following these strong results, CVS Health raised its full-year 2026 earnings guidance to a new range of $7.30 to $7.50 per share. As highlighted by Reuters, this updated forecast is based on improved medical cost controls and strong performance in its pharmacy management business. The company's operating income also surged by 38.7% to $4.68 billion, further solidifying its financial outlook and making CVS stock an attractive prospect for investors.